[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"homeostatic-iron-regulator-gene-related-hereditary-hemochromatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:homeostatic-iron-regulator-gene-related-hereditary-hemochromatosis":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100618474",false,"NCT07332091","Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis","A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)","Inclusion Criteria:\n\n* Adult (≥ 18 years) and has provided written informed consent.\n* Confirmed diagnosis of HFE-HH in medical history.\n* Evidence of iron overload as shown by:\n\n  * TSAT \\> 45% (confirmed at 2 visits, at least 14 days apart) at Screening; and\n  * Serum ferritin ≥ 200 nanogram per milliliter (ng\u002FmL) and \\\u003C 5000 ng\u002FmL (confirmed at 2 visits, at least 14 days apart) at Screening; and\n  * MRI-based LIC between 3 and 16 mg\u002Fg (53.7 and 286.5 millimol per kilogram \\[mmol\u002Fkg\\]) dry weight (dw) at Screening.\n* Body mass index between 18.5 and 32 kilograms per meter squared (kg\u002Fm\\^2).\n\nExclusion Criteria:\n\n* Clinically relevant laboratory abnormalities, 12-lead electrocardiogram (ECG) findings, or medical history.","ALL","18 Years",{"count":18,"type":19},84,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.",[25],"Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis",[27,28,29],"Small Molecule Ferroportin Inhibitor","Hereditary hemochromatosis","Iron overload","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2026-01-22",{"date":38,"type":19},"2028-04-06",{"name":40,"class":41},"CSL Behring","INDUSTRY",98,""]